in vivo remains challenging because of the low frequency and often poor durability of transduced t cells over time when transferred without enrichment. traditional methods often require additional overnight in vitro culture after transduction. Moreover, in vitro-generated effector cD8 + t cells enriched by sorting often have reduced viability, making it difficult to monitor the fate of transferred cells in vivo. Here, we describe an optimized mouse cD8 + t-cell rV transduction protocol that uses simple and rapid percoll density centrifugation to enrich rV-susceptible activated cD8 + t cells. percoll density centrifugation is simple, can be done on the day of transduction, requires minimal time, has low reagent costs and improves cell recovery (up to 60%), as well as the frequency of rV-transduced cells (~sixfold over several weeks in vivo as compared with traditional methods). We have used this protocol to assess the long-term stability of cD8 + t cells after rV transduction by comparing the durability of t cells transduced with retroviruses expressing each of six commonly used rV reporter genes. thus, we provide an optimized enrichment and transduction approach that allows long-term in vivo assessment of rV-transduced t cells. the overall procedure from t-cell isolation to rV transduction takes 2 d, and enrichment of activated t cells can be done in 1 h.
IntroDuctIon
T cells have a key role in combating cancer and infection by intracellular pathogens. Therapeutically improving the effectiveness of T cells for vaccines or immunotherapies requires a detailed understanding of the molecular mechanisms of T-cell differentiation. A major challenge of these studies is that many of the key events involved in development of highly functional T cells do not occur in vitro and can be analyzed in detail only by using in vivo models [1] [2] [3] . Thus, to interrogate GOIs in T-cell differentiation in vivo, it is critical to be able to trace T cells with manipulation of the GOIs in vivo over long time frames (weeks to months), during which T-cell memory or exhaustion, in the case on chronic infections or cancer, can form. Genetic manipulation of mouse genomes has been a mainstay of research on T-cell memory and exhaustion, and it has become even more facile with the development of CRISPR technologies. However, developmental concerns, the cost of maintaining large animal colonies, concerns about controlling for systemic effects and the speed with which manipulations on the genetic level can be performed are still limiting factors when designing such experiments.
Retroviral transduction approaches have several advantages, including rapid construction, methods to control gene expression or function, the ability to incorporate reporter genes to monitor only transduced cells and the ability to be applied to multiple genetic backgrounds (e.g., transduction of wild-type versus genetic knockout cells) [4] [5] [6] [7] . A major advantage of such approaches for experimental models of effector, memory and exhausted T-cell biology is the ability to adoptively transfer RV-transduced T cells in vivo and monitor their differentiation ( Fig. 1; refs. [8] [9] [10] . There are several methods or protocols describing RV transduction of T cells in the context of adoptive T-cell transfer therapy using human peripheral CD8 + T cells and general protocols for mouse T cells [5] [6] [7] [11] [12] [13] [14] [15] . However, few publications describe details of RV transduction for CD8 + T cells for long-term use in vivo. Indeed, monitoring of RV-transduced T cells long term in vivo remains challenging for several reasons. First, the frequency of RV-transduced T cells often decreases after adoptive transfer in vivo, making detailed studies at late time points challenging (Fig. 2) . Often, high numbers of RV-transduced T cells are transferred to circumvent this limitation. However, in some settings, the precise number of transferred CD8 + T cells is critical to the pathogenesis of infection 16 . In addition, adoptively transferring unphysiologically high numbers of CD8 + T cells can distort the normal pattern of memory differentiation 17 . Therefore, approaches that allow RV-transduced T cells to be used at numbers that approximate the endogenous antigen-specific T-cell response and also allow long-term monitoring would be a major advantage. Enriching for RV-transduced T cells before transfer can improve these approaches. However, flow-cytometric-based or magnetic-bead-based enrichment methods usually require additional overnight in vitro culture to allow reporter gene expression, potentially contributing to some of the inefficiencies described above. Moreover, in vitro-generated effector CD8 + T cells that are enriched by flow-cytometric sorting often show significantly reduced cell viability (P < 0.0005; see Fig. 3e for data), potentially due to mechanical stress and/or surface staining with antibodies that could cause rejection. A second challenge for in vivo studies using RV-transduced T cells is the choice of reporter genes/ proteins for transduction. Multiple genes, including GFP, violetexcited fluorescent protein (VEX), monomeric Kusabira Orange 2 (mKO2), mCherry, Thy1.1 and human nerve growth factor receptor (hNGFR), have been used as RV reporters. However, there is the potential for these reporter genes and the proteins they encode to serve as rejection antigens, leading to deletion of RV-transduced cells by the host immune system 18 . Therefore, compatibility of markers used as reporters of RV transduction with long-term in vivo T-cell persistence is essential, but a systematic comparison of reporter genes for use in T-cell-memory studies is lacking. Thus, there is a need for an optimized, flexible and efficient RV transduction approach that allows efficient manipulation of the GOI for the study of long-term T-cell biology, T-cell durability and memory differentiation in vivo.
Here, we describe a step-by-step protocol for RV transduction of mouse CD8 + T cells that uses Percoll density centrifugation to enrich RV-susceptible cells. This approach improves the viability of RV-transduced cells and enables more efficient long-term T-cell memory and exhaustion experiments with RV-transduced T cells in vivo ( Figs. 1 and 2) . In previously published research from our group 9, 10 , we have applied this optimized RV transduction protocol to track and analyze RV-transduced CD8 + T cells in both acute and chronic viral infection mouse models for more than 10 weeks after transfer in vivo.
Development and overview of the protocol
Two keys to improving the efficiency of in vivo CD8 + T-cell RV-transduction studies are to enrich RV-transduced (or RVsusceptible) T cells while minimizing cell stress and to adoptively transfer cells to recipient mice as soon as possible (ideally within a few hours) after RV transduction. RV are typically used for gene delivery into mouse T cells, as most lentiviruses transduce mouse T cells poorly 7 . However, unlike lentiviruses, which can transduce resting human T cells, RV transduction is restricted to proliferating cells 4 . Thus, an in vitro T-cell activation strategy is used to induce susceptibility of CD8 + T cells to RV transduction (Fig. 1 ) [5] [6] [7] 15 . To begin to develop an optimized RV approach for long-term in vivo studies, we initially examined RV-transduced CD8 + T cells 1 d after transduction (day 2 after in vitro stimulation; Figs. 1 and 2a) . At this stage, RV-transduced cells are found almost entirely within the large-sized 'blasting' (i.e., more activated and susceptible to RV transduction) gate by flow cytometry (Fig. 2a) . By contrast, very few RV-transduced CD8 + T cells in the population of live CD8 + T cells remain as small-sized 'resting' cells after 48 h of in vitro stimulation with soluble anti-CD3ε and CD28 antibodies (Fig. 2a) . T cells that are primed later in vivo and receive less stimulation during initial activation have been reported to have an advantage in differentiating into memory T-cell populations in vivo 1, 19 . Alternatively, weakly activated or nonactivated (i.e., still-naive T cells) might be efficiently primed upon adoptive transfer to infected mice. Thus, we hypothesized that the residual small-sized cells might engraft and proliferate in vivo more efficiently compared with the blasting population. If true, this could result in a greater decline in the RV-transduced blasting cell population at later time points. To test this idea and circumvent this potential problem, we devised a simple strategy to separate these two T-cell populations. Previously activated human lymphocytes have been separated by density centrifugation because of their lower overall density 20, 21 . Thus, we tested whether Percoll density centrifugation could also enrich the larger-sized 'blasting' T cells on day 1 after in vitro stimulation ( Fig. 2b) 22 . As expected, large-sized 'blasting' cells that have the capability to differentiate into true effector T cells after additional overnight in vitro culture are efficiently enriched in the thin layer between the 30 and 60% (vol/vol) Percoll in the Percoll density gradient on day 1 (Fig. 2b,c, Supplementary Fig. 1 ). By contrast, small-sized 'resting' cells that are not fully able to differentiate into blasting effectors are removed into the bottom fraction (Fig. 2b,c, Supplementary Fig. 1 ). We find that the recovery of the large-sized cells by Percoll is up to 60% (Fig. 2c, Supplementary  Fig. 1b,d , black bar), higher than typical sorting-based enrichment for this blasting population (normally 10-20%, Fig. 3c ). Next, we examined whether this enrichment of blasting cells on day 1 can improve the frequency of RV-transduced T cells in vivo. After in vivo transfer, ~60-65% of the donor CD8 + T-cell population was RV-transduced on day 8 as compared with only 10-12% in the case of the unenriched population ( Fig. 2d ; see Supplementary  Fig. 2 for staining and gating strategy used to detect antigenspecific CD8 + T cells in vivo in this study). In separate experiments, we directly compared the frequency of RV-transduced T cells on day 8 in vivo for the following groups of donor cells: nonenriched, interface only, bottom only or a re-mixture of interface and bottom cells, all isolated from the same activated P14 CD8 + T-cell source (Supplementary Fig. 3a) . As expected, enrichment and adoptive transfer of resting cells results in recovery of a low frequency of RV-transduced T cells, based on the RV-reporter + frequency from day 2 to day 8 ( Supplementary  Fig. 3b,c) . Moreover, add-back of resting cells to blasting cells before adoptive transfer decreases the frequency of RV-transduced T cells among the donor T-cell pool on day 8, supporting the idea that resting cells in the cell transfer mixture outcompete blasting cells and reduce efficiency of detection of RV-transduced cells at later time points in vivo ( Supplementary Fig. 3b,c) . Percoll density centrifugation also improves the stability and durability of RV-transduced cells over several weeks in vivo (Fig. 2e-g ). Moreover, Percoll-based enrichment minimizes the variance of frequency of RV-transduced T cells in vivo, contributing to more statistically reliable results (Fig. 2g) . Centrifugation does not appear to alter T-cell differentiation, as effector and memory CD8 + T cells derived from Percoll enrichment are similar to those from non-Percoll-treated controls in terms of surface phenotype and cytokine production after lymphocytic choriomeningitis virus (LCMV) Armstrong (Arm) infection (Fig. 2h,i) . These data in Figure 2h also demonstrate identification of memory precursor populations (i.e., CD127 hi KLRG1 lo ) in the RV-transduced T-cell pool. These data indicate that although we are purifying a more activated fraction of in vitro-activated CD8 + T cells, at least some cells in this pool are capable of giving rise to memory precursor cells. Overall, use of a simple Percoll density centrifugation approach enriches for RV-transduced CD8 + T cells after in vitro activation while minimizing cellular stress. This approach substantially improves the in vivo efficiency of RV-transduced memory or exhausted CD8 + T-cell experiments by increasing transduced cell yields and improving the in vivo durability of transduced CD8 + T-cell populations.
Application of the protocol
The protocol described here was developed specifically for CD8 + T-cell studies in a viral infection mouse model. However, it is likely that the basic concept of Percoll separation has multiple applications and a wider interdisciplinary utility, including those for (i) T-cell responses in other disease contexts such as cancer immunology or autoimmunity; (ii) other hematopoietic subsets, such as CD4 + T cells (see below), B cells and bone-marrow-progenitor cells; and (iii) broader biological fields, in which RV transduction target cells are heterogeneous in terms of cell proliferation and size (i.e., density). Of note, this protocol is independent of specific molecules (e.g., GFP) derived from target cells or RV for T-cell enrichment. Thus, we believe that this protocol can be easily applied to general RV transduction experiments.
Advantages
Flow-cytometric sorting or magnetic-bead-enrichment approaches have traditionally been used to enrich RV-transduced CD8 + T cells before adoptive transfer into recipient mice. Compared with these two approaches, enrichment using Percoll density centrifugation has several advantages. First, flow-cytometric sorting requires the expression of RV-derived reporter genes, and additional days of cell culture are required for these genes to be expressed after RV transduction (Fig. 3) . By contrast, enrichment using Percoll can be done on the same day as RV transduction, reducing the time CD8 + T cells are cultured in vitro before adoptive transfer to mice. For optimal CD8 + T-cell differentiation, particularly for long-lived memory CD8 + T-cell studies, in vitro-stimulated CD8 + T cells perform better when adoptively transferred into recipient mice early after initial activation, perhaps because of preservation of memory precursor cells in the early activated pool. Thus, the ability to minimize the duration of in vitro culturing by using density centrifugation on day 1 after activation is likely to have advantages for long-term in vivo T-cell studies. Second, enrichment by flow sorting can lead to low overall experimental efficiency (i.e., cell recovery and engraftment after transfer) for RV-transduced T cells (Fig. 3) . This inefficiency could be due to mechanical damage to the blasting T cells during sorting due to high pressure and/or shear stress. In addition, some antibodies used to stain reporter markers (e.g., Thy1.1) could potentially cause antibody-dependent cell depletion after transfer. Because enrichment by Percoll does not involve any shear stress or staining, Percoll density centrifugation maintains T-cell integrity and, as a result, yields highly reproducible and stable results with better cell recovery (Figs. 2b-g and 3c-e) . Third, Percoll density centrifugation is substantially less expensive and faster than alternative approaches. Density centrifugation does not require any special or expensive equipment, and reagent cost is minimal. In addition, enrichment by Percoll can be done in 1 h, whereas flow sorting typically requires several hours and additional technical expertise to complete.
Limitations
Although overall cell recovery is improved using Percoll density centrifugation as compared with flow-cytometric sorting, we have found that increasing the initial number of T cells is useful in minimizing cell loss ( Fig. 4 ; see optimal number of transferred T cells for detail). This requirement typically results in using more TCR transgenic mice as donors for T cells to be transduced. In a typical experiment for which one might need five to ten recipient mice per RV, ~10 7 starting T-cell-receptor (TCR) transgenic T cells (i.e., ~1 donor spleen) per RV appear optimal. An additional limitation to this protocol is that although Percoll enriches highly activated T cells, it is possible that the purified T cells could show slightly modified differentiation due to either subtleties in the population purified or due to the effects of Percoll itself. Although this issue has not been observed in our initial studies, it is, of course, valuable to use the same enrichment protocol for a control population (i.e., an empty RV containing only the reporter gene) when analyzing the effects of the RVexpressed GOI in vivo. A third limitation is overall the purity of transduced populations. Although the efficiency of in vivo recovery and persistence is improved with the Percoll approach, if highly purified populations are needed, flow-cytometric sorting (for which purity can reach over 95%, Fig. 3a) will still have an advantage. RV non-transduced, but activated blasting cells, will be contained in the Percoll-purified populations (purity of RV-transduced cells is ~50-60%; Fig. 2d ). In some settings, these nontransduced populations can be a useful control (in addition to the empty RV control). However, in other situations in vivo readouts such as pathogen burden or tumor control will be affected by the total number of adoptively transferred cells, especially when TCR transgenic populations are used. Thus, purity of RV-transduced populations will be a major consideration in some settings. One advantage, of course, of such RV approaches is the ability to introduce the GOI into T cells from different genetic backgrounds, such as re-introducing mutant forms of a protein into T cells genetically deficient in that protein. In some settings, genetic deficiency might alter initial T-cell activation, changing the efficiency of this Percoll approach. In such settings, it may be possible to transduce bone marrow T-cell progenitors, followed by adoptive transfer to recipient mice to allow T-cell development to occur for the generation of mature T cells that can be used to address the question of interest 23, 24 . CD4 + versus CD8 + T cells. In this protocol, we mostly focused on CD8 + T cells. However, we also tested key observations in CD4 + T cells and found that activated 'blasting' CD4 + T cells can also be enriched by Percoll centrifugation when the same stimulation method with anti-CD3ε, anti-CD28 antibodies and rhIL-2 was used ( Supplementary Fig. 4a-c) . Further optimization will be needed, for example, to compare different CD4 + T-cell-polarization culture conditions. Preparation of RV stock. As there is a tropism between RV pseudotype and type of target mammalian cells, it is critical to use the appropriate RV system in each experimental setting 4, 15 . To balance biosafety and higher transduction efficiency, we have used an ecotropic murine stem-cell virus-based RV system in our work that can transduce only rodent cells. Detailed protocols for preparation and titration of RV have been described previously [4] [5] [6] [7] 14, 23, 25 . Although use of freshly prepared RV supernatant is recommended in other fields, frozen RV stocks can be used for transduction of CD8 + T cells 5 . RV stocks can be stored at −80 °C for up to 2 years without noticeable loss of transduction efficiency. In addition, as there can be variability in RV titers among production batches, using frozen stocks of virus for which the titer has been previously verified is recommended.
Experimental design
Isolation and in vitro stimulation of CD8 + T cells. As the frequency of antigen-specific T cells in a polyclonal setting is extremely low, use of T-cell-receptor transgenic (TCR Tg) animals facilitates many aspects of these studies. In our studies, we used LCMV infection and LCMV glycoprotein H-2D b /gp33-41-specific 'P14' TCR Tg CD8 + cells 9, 10, 26 . In addition, the spleen is an ideal source for T cells; however, the frequency of CD8 + T cells among splenic mononuclear cells is only ~15-20%. Moreover, it was reported that the purity of target cells at RV transduction affects transduction efficiency 5 . Thus, purification of CD8 + T cells before in vitro stimulation is important (Fig. 1) . For T-cell activation, there are multiple options, including phorbol myristate acetate and ionomycin, concanavalin A, soluble antibodies and cognate peptide, in the case of TCR Tg cells 5, 6, 15, 27 . In our experience, stimulation with soluble anti-CD3ε and anti-CD28 is a highly efficient and easy method of T-cell activation for RV transduction purposes (Fig. 1) . As an alternative method, stimulation with cognate peptide has been described 14 . In our studies, we have found that cognate peptide stimulation results in lower T-cell survival after transfer (data not shown), perhaps because T cells themselves can acquire peptides and recognize and kill each other or because of the poor availability of professional antigen-presenting cells, such as dendritic cells, in the purified CD8 + T-cell cultures.
T-cell enrichment for RV transduction. Detailed information on Percoll and density centrifugation has been provided previously 22, 28 . To obtain the optimal combination of Percoll concentrations for activated T-cell separation, we have compared different combinations of Percoll solutions for two layers from 10 to 90% in 10% steps and found that a combination of 30% (vol/vol) for the upper and 60% (vol/vol) for the lower Percoll layer results in the best separation (data not shown). However, the type of centrifuge and/or rotor, temperature and production lot of the reagents and plastic tubes could influence separation efficiency 28 . Thus, slight modification by changing Percoll concentrations in 5% steps may be helpful for further optimization. Furthermore, the activation status of target T-cell populations, which can directly influence cell density, has a strong impact on gradient separation efficiency. Cell density during in vitro stimulation and, more importantly, the timing since initial stimulation in culture are major factors for T-cell activation status. In our experience, even a few hours' difference from in vitro stimulation (e.g., 18 h versus 22 h versus 25 h) can result in a large change in activation status (see cell size in forward scatter versus side scatter flow plots in Supplementary Fig. 1a (18 h),  Fig. 2b (22 h) and Supplementary Fig. 1c (25 h)) , and, as a result, in subsequent Percoll separation and RV-transduction efficiency in vivo. Therefore, the conditions of in vitro stimulation and timing should be carefully determined.
In our experience, whether Percoll enrichment is used before or after RV transduction does not affect RV-transduction efficiency if the same number of T cells is used for the RV-transduction step (i.e., if the T-cell/RV ratio is fixed) (data not shown). It may be possible to increase the efficiency of transduction slightly by reducing the number of blasting cells per well (i.e., a higher multiplicity of infection). However, this will also result in greater consumption of RV supernatants. As the overall cell recovery after Percoll density enrichment is ~30%, our approach has been to perform Percoll density centrifugation first to limit the amount of RV used. In addition, when RV transduction precedes Percoll enrichment, activated T cells are often divided into multiple groups (i.e., for each different RV), resulting in smaller cell numbers per condition. In such settings, it may be more challenging to efficiently recover RV-transduced T cells after Percoll treatment because of low starting cell numbers.
Conditions of RV transduction.
The efficiency of RV transduction can be improved by modifying three factors. (i) Timing: once stimulated in vitro, CD8 + T cells start to divide within ~24-30 h and continue to proliferate for ~ 4-5 d, provided conditions are optimal. However, the susceptibility of mouse CD8 + T cells to RV transduction peaks at 24 h after in vitro stimulation (Fig. 5a ) [5] [6] [7] 15, 27 . Thus, for the highest efficiency, RV transduction of mouse CD8 + T cells should be performed at 1 d after in vitro stimulation (Figs. 1 and 5a) . We also found that mouse CD4 + T cells have the highest susceptibility to RV transduction at 48 h after in vitro stimulation (Supplementary Fig. 4d). (ii) Repetition and incubation time: to maximize RV-transduction efficiency, multiple rounds of transduction or extended incubation time (>4 h) have been described in some protocols 5, 15 . However, provided that RV titers are sufficiently high and target CD8 + T cells are appropriately activated in vitro, the efficiency reaches 60-80% with single-RV-transduction and 4-h incubation in most cases (Fig. 2d) 15 . Thus, in this protocol we use a single round of spintransduction and 4 h for incubation, and we transfer T cells into recipients as early as possible (Fig. 1) . (iii) Facilitators: electronic charge repulsion between RV and sialic acid on the cell surface can reduce RV-transduction efficiency 29 . To facilitate adsorption of RV to target cells, multiple reagents, including Polybrene (hexadimethrine bromide) and RetroNectin (recombinant human fibronectin fragment) have been used 5, 15, 29 . We have directly compared Polybrene and RetroNectin in the context of CD8 + Tcell RV experiments and found that RetroNectin results in higher transduction efficiency (Fig. 5b, top four samples) ; however, RetroNectin requires additional time for preparation of coated plates and is more expensive than Polybrene. Alternatively, we also found that, in the case of Polybrene, use of non-tissue-culturetreated plates yields slightly better transduction efficiency with increased reporter gene (GFP) signal intensity (Fig. 5b, bottom  two samples) .
Optimal number of adoptively transferred CD8 + T cells.
As mentioned above, one key factor to consider for studies using RV-transduced TCR Tg T-cell populations is the number of cells to be adoptively transferred. In some settings, it may be critical to match the number of adoptively transferred TCR Tg cells as closely as possible to that of endogenous antigen-specific T cells because of the effects on memory CD8 + T-cell differentiation 17 or impacts on pathogenesis 16 . Many variables may impact how T cells behave in vivo and thus influence the choice of the number of RV-transduced T cells to be adoptively transferred. These variables include the following: the RV-expressed GOI itself; the nature of donor TCR Tg cells (e.g., affinity of TCR, wild type versus knockout); viability of donor TCR Tg cells (e.g., cell density during in vitro stimulation, method of in vitro stimulation and toxicity of Polybrene); and type and dose of antigen challenge in vivo (i.e., infection versus cancer, virus versus bacteria and acute versus chronic infection). Moreover, Percoll enriches more activated T cells, suggesting that T-cell response kinetics could differ between non-Percoll and Percoll purification approaches. Thus, the number of transferred TCR Tg cells should be optimized in an individual experimental setting. For example, we have titrated the number of P14 cells in the LCMV Arm acute virus infection model and found that when enriched by Percoll, transferring 1 × 10 5 wild-type P14 cells results in a response that is similar in magnitude to the endogenous host gp33-specific CD8 + T-cell response (Fig. 4a,b) . Increasing the number of transferred P14 cells does not affect the frequency of RV-transduced cells, but it does minimize variance (Fig. 4c) . As a result, transferring 1 × 10 5 Percoll-enriched P14 cells increases the number of RV-transduced CD8 + T cells by several fold as compared with 2 × 10 4 nonenriched P14 cells, while keeping the total P14 cell response similar to the endogenous level (Fig. 4b,d ).
RV reporter genes (proteins) for long-term in vivo analysis.
Flexibility of reporter markers is a key advantage of RV experiments. For example, whereas cytosolic fluorescent protein markers (e.g., GFP, VEX, mKO2 and mCherry) are suitable for live-cell enrichment by sorting, membrane protein markers (e.g., Thy1.1 and hNGFR) have flexibility in the choice of staining reagents and have stronger resistance to fixation and permeabilization. GFP cannot be used as an RV reporter gene for cells already expressing GFP or for some analytic applications that require specific fluorescent reagents with emission spectra that overlap or interfere with GFP (e.g., a mitochondrial analysis dye such as Mito Tracker Green). In addition, combining multiple RVs allows double or triple transduction within individual cells. Therefore, having multiple options for RV reporter genes expands the experimental applications and opportunities. However, some reporter genes used to monitor RV-transduced cells may become rejection antigens and/or cytotoxic (e.g., aggregation of reporter proteins in cytoplasm or altered cell signaling can damage cell viability), leading to loss of RV-transduced cells over time 18 . However, there is little direct comparative analysis of this topic for long-term T-cell biology in vivo. Thus, we compared the use of six RV reporter genes (GFP, VEX, mKO2, mCherry, Thy1.1 and hNGFR) by monitoring cell number over time and memory differentiation for RV-transduced CD8 + T cells [30] [31] [32] [33] (Fig. 6) . We found that CD8 + T cells transduced with empty RV vectors expressing GFP, VEX, mKO2 or Thy1.1 RV showed stable frequencies of transduced cells over time once transferred in vivo (Fig. 6a-c) . By contrast, the RV reporters mCherry and hNGFR resulted in loss of RV-transduced cells over time, suggesting rejection or other mechanisms of poor durability for these reporter genes (Fig. 6a-c) . In addition, we found that GFP, VEX, mKO2, mCherry or Thy1.1 RV-transduced CD8 + T cells showed similar surface phenotype and cytokine production on day 36 after infection ( Fig. 6d,e) . Taken together, GFP, VEX, mKO2 and Thy1.1 allow long-term stability of RV-transduced T cells in C57Bl/6 mice, facilitating detailed experiments of T-cell memory or exhaustion over time in vivo.
Improved detection of RV-transduced cells by additional fixation.
One challenge when analyzing RV-transduced T cells using intracellular staining (ICS) for flow cytometry is that loss of signal for some fluorescent proteins derived from RV (e.g., GFP, VEX or mKO2) after permeabilization of the cell membrane makes it difficult to detect all of the RV-transduced cells. A previous study by Heinen et al. showed that commonly used permeabilization kits for ICS assays have weak fixation reagents, thus resulting in the loss of some cytoplasmic molecules, including fluorescent proteins 34 . This same study also showed that an additional fixation step increased GFP retention in the cytoplasm of permeabilized cells. Thus, we tested whether an additional fixation before permeabilization with commercial kits could improve the detection of fluorescent proteins derived from RV transduction in T cells. As shown in Figure 7 , pre-fixation with 2% (wt/vol) PFA improves the detection of RV-transduced cells ~tenfold, and a similar frequency as compared with no permeabilization is observed. Figure 6 are representative of two independent experiments (n = 9-10 per group). Mean ± s.e.m. All animal experiments depicted in Figure 6 were performed in accordance with the institutional animal care and use guidelines of the University of Pennsylvania. 
Density centrifuge and RV transduction
Percoll (GE Healthcare, cat. no. 17-0891-01) PBS, 10×, no calcium, no magnesium (Gibco, cat. no. 14200-075) NaHCO 3 , 7.5% (wt/vol) (Gibco, cat. no. 25080-094) Polybrene (hexadimethrine bromide; Sigma-Aldrich, cat. no. H9268) RetroNectin (Takara-Clontech, cat. no. T100A or T100B) Refrigerator Retrovirus supernatant ! cautIon Universal precautions must be taken while handling RV supernatants and RV-transduced samples, and all experiments must be carried out in at least class II biological safety cabinets and using appropriate protection equipment (e.g., lab coat, eye protection and gloves).  crItIcal It is important to determine the titer of RV stock in advance. The RV titer can be determined as described in previous protocols 13, 15 . RV titer can vary among production batches and will affect downstream experiments. Flow cytometry 7-AAD (BioLegend, cat. no. 420403) 4% (wt/vol) Paraformaldehyde (PFA) in PBS (Affymetrix, cat. no. 19943) ! cautIon PFA is toxic and irritating to the skin, eyes and respiratory system, and it may be carcinogenic; wear protective gloves and work under a chemical hood while preparing the solution. Fluorescently labeled anti-mouse CD8, CD45.1 and CD45.2 (if applicable) antibodies (all antibodies used in this study are listed in Supplementary  Table 1 )  crItIcal Each antibody should be titrated before use.  crItIcal All antibodies must be kept at 4 °C and protected from exposure to direct light.  crItIcal Choose an appropriate fluorescent color and avoid FITC (for GFP RV), AmCyan/BV510 (for VEX RV), PE (for mKO2 RV) or PE Texas Red (for mCherry) for specific RV reporter genes. Fluorescently labeled anti-mouse/rat CD90.1 (Thy1.1) or anti-human CD271 (NGFR) antibodies if Thy1.1 or hNGFR RV is used  crItIcal Each antibody should be titrated before use. Foxp3 Transcription Factor Staining Buffer Set (eBioscience, cat. no. 00-5523-00) ! cautIon Fixation buffer contains PFA and is toxic; wear protective gloves and work under a chemical hood while preparing the solution. 
EQUIPMENT
stock in 1.5-ml microcentrifuge tubes and store them at −80 °C for up to 1 year. To make the 10 2 U/µl working stock, add 990 µl of sterile PBS to 10 µl of 10 4 U/µl master stock. Prepare 100-µl aliquots of working stock in 1.5-ml microcentrifuge tubes, and store them at -20 °C for up to 1 year. Complete RPMI-1640 (1,000 ml) Add 100 ml of FBS (final = 10% (vol/vol)), 1 ml of 50 mM 2-mercaptoethanol (final = 0.05 mM), 10 ml of 10,000 U/ml penicillin and 10,000 µg/ml streptomycin (final = 100 U/ml and 100 µg/ml, respectively), 20 ml of 1 M HEPES (final = 20 mM), 10 ml of 100 mM sodium pyruvate (final = 1 mM), 10 ml of 10 mM nonessential amino acids (final = 100 µM) to 1,000 ml of RPMI-1640 medium. Filter-sterilize the medium through a 0.22-µm bottle top filter unit, and store it at 4 °C for up to 2 weeks. T-cell stimulation medium (50 ml) Add 50 µl of 1 mg/ml anti-mouse CD3ε antibody (final = 1 µg/ml), 25 µl of 1 mg/ml anti-mouse CD28 antibody (final = 0.5 µg/ml), and 50 µl of 100 U/µl rhIL-2 (final = 100 U/ml) to 50 ml of complete RPMI-1640 medium. Store the medium at 4 °C for up to 2 weeks.  crItIcal It is important to add IL-2 and 2-mercaptoethanol to the T-cell stimulation medium. Transduction efficiency is <10% in the absence of IL-2. Isotonic Percoll (270 ml) Transfer 231.25 ml of Percoll to an autoclaved glass bottle. Add 36 ml of 10× PBS and 3.26 ml of 7.5% (wt/vol) NaHCO 3 .
Store the solution at 4 °C for up to 1 year.  crItIcal As Percoll can form precipitates during long-term storage, shake the bottle vigorously before using. 30 and 60% (vol/vol) Percoll Add 2.8 ml of complete RPMI-1640 medium to 1.2 ml of isotonic Percoll to make 4 ml of 30% (vol/vol) Percoll solution. Add 1.2 ml of complete RPMI-1640 medium to 1.8 ml of isotonic Percoll to make 3 ml of 60% (vol/vol) Percoll solution.  crItIcal To avoid any risk of Percoll sedimentation and bacterial contamination, it is advised to use freshly prepared Percoll solutions. Polybrene (800 and 8 mg/ml) Dissolve 5 g of Polybrene in 6.25 ml of water to make an 800 mg/ml master stock. Take 1 ml of master stock and add 99 ml of water to make an 8 mg/ml working stock. Stocks can be stored in a 1.5-ml or 2-ml tube at −20 °C for at least 1 year. RetroNectin coating of a six-well plate For coating one well of a six-well plate, add 40 µl of RetroNectin (1 µg/µl) to 1,960 µl of PBS to make 2 ml of 20 µg/ml solution. Apply 2 ml of 20 µg/ml RetroNectin solution per well of the non-tissue-culture-treated six-well plate. Incubate the plate at 4 °C overnight. Remove the RetroNectin solution. Wash the plate twice with ice-cold PBS and use it immediately. 2% (vol/vol) PFA (100 ml) Add 50 ml of PBS to 50 ml of 4% (vol/vol) PFA in PBS. Store the solution at 4 °C for up to 1 month. ! cautIon PFA is toxic; wear protective gloves and work under a chemical hood while preparing and using this solution. MACS buffer (1,000 ml) Add 10 ml of serum (final = 1% (vol/vol)) and 4 ml of 0.5 M EDTA (final = 2 mM) to 1,000 ml of PBS. Store the buffer at 4 °C for up to 1 month.
proceDure Isolation and in vitro stimulation of cD8 + t cells • tIMInG 3 h ! cautIon Appropriate institutional regulatory board permission for animal infection experiments must be obtained before you start mouse experiments. All animal work in this study was performed in accordance with the institutional animal care and use guidelines for the University of Pennsylvania. 1| Ensure that you have sufficient numbers of donor mice.  crItIcal step Because adoptively transferred T cells will be analyzed over several weeks to months in vivo in some experiments, it is important to match the genetic backgrounds of donor CD8 + T cells and recipient mice to avoid potential rejection issue. See Reagents for details.  crItIcal step Generally, consider preparing one donor mouse per RV. See 'Limitations' and 'ANTICIPATED RESULTS' for more detail.
? trouBlesHootInG 2| Euthanize mice according to institutional guidelines (e.g., we use a lethal dose of CO 2 narcosis, followed by cervical dislocation).
! cautIon Experiments involving mice should be performed according to all relevant governmental and institutional guidelines and regulations, in compliance with protocols approved by local animal ethics committees. All animal work in this study was performed in accordance with the institutional animal care and use guidelines for the University of Pennsylvania.  crItIcal step Time from in vitro stimulation on day 0 to RV transduction on day 1 is an important parameter for optimal RV transduction efficiency. A stimulation time of at least 18 h, but no more than 48 h, is required for optimal CD8 + T-cell activation and subsequent RV transduction (Fig. 5) . In addition, the entire experimental procedure on day 1, from enrichment of activated T cells to adoptive transfer by injection, can typically take at least 9 h. Thus, to start and finish day 1 procedures efficiently (e.g., between 9 a.m. and 6 p.m.), we recommend starting in vitro stimulation early on day 0. ? trouBlesHootInG 3| Spray 70% (vol/vol) ethanol over the mouse body, and collect the spleens in a 70-µm sterile cell strainer immersed in 2 ml of MACS buffer (Reagent Setup) and placed in a sterile 60-mm cell culture dish on ice.
4| Dice the spleens into 2-to 3-mm pieces before smashing them on the 70-µm cell strainer.  crItIcal step This step is important to maximizing cell recovery and viability.
5|
Prepare a single-cell suspension by crushing the spleen through the strainer in MACS buffer.  crItIcal step For the best T-cell viability, we recommend not using a red blood cell (RBC) lysis buffer such as ammonium-chloride-potassium (ACK) buffer.
6|
Transfer the spleen cell suspension to a 15-ml conical tube.
7|
Wash the 70-µm cell strainer by passing 8 ml of MACS buffer over the 60-mm cell culture dish.
8|
Combine the MACS buffer containing residual spleen cells from the 60-mm cell culture dish with the spleen cell suspension in the 15-ml tube (from Step 6).
9|
Centrifuge the 15-ml tube at 300g for 5 min at 4 °C.
10|
Aspirate the supernatant.
11|
Resuspend the cell pellet in 1 ml of MACS buffer per spleen.
12| Enrich CD8 + T cells by CD8 negative selection. As we normally use a kit from StemCell Technologies, we describe the protocol for the EasySep Mouse CD8 + T Cell Isolation Kit (Reagents) here.  crItIcal step Most commercial kits are likely to work. However, inclusion of anti-RBC antibody (e.g., Ter-119) in the kit is essential if RBC lysis buffer is not used during spleen processing.
13| Add 50 µl of rat serum (provided in the kit) per 1 ml of spleen cell suspension.
14|
Add 50 µl of Isolation Cocktail per 1 ml of spleen cell suspension.
15|
Mix the contents and incubate them at room temperature for 10 min.
16|
Vortex the RapidSpheres (provided in the EasySep Mouse CD8 + T Cell Isolation Kit) for 30 s.
17| Add 125 µl of RapidSpheres per 1 ml of spleen cell suspension.
18|
Mix the contents and incubate them at room temperature for 5 min.
19| If the cell suspension volume is <4 ml, bring the volume to 5 ml by adding MACS buffer; if the cell suspension volume is >4 ml, bring the volume to 10 ml by adding MACS buffer. 
20|
Mix the contents by gently pipetting up and down two to three times. Remove the cap from the 15-ml tube.
21|
Place the tube without the cap into the magnet, and leave it for 2.5 min at room temperature. In the meantime, prepare a new 15-ml tube.
22|
Pick up the magnet, and, in one continuous motion, invert the magnet and tube, and pour the enriched CD8 + T-cell suspension into the new 15-ml tube.
23| Count the number of cells using a hemocytometer or any other cell counter. Normally, at least 5 × 10 6 cells per spleen are recovered.
24|
On the basis of the number of cells, prepare an appropriate volume (1 ml per 1 × 10 6 cells) of T-cell stimulation medium in a separate tube or flask by adding anti-CD3ε (final = 1 µg/ml), anti-CD28 (final = 0.5 µg/ml) antibodies and rhIL-2 (final = 100 U/ml) to complete RPMI-1640 medium (Reagent Setup).  crItIcal step Testing the serum lot for T-cell culture in advance is recommended.  crItIcal step Make sure to add 2-mercaptoethanol to the complete RPMI-1640 medium. 2-mercaptoethanol is essential to keep IL-2 activity in the medium and facilitate CD8 + T-cell activation.
? trouBlesHootInG
25|
Centrifuge the enriched CD8 + T-cell suspension at 300g for 5 min at 4 °C.
26|
Aspirate the supernatant and resuspend the cell pellet with stimulation medium in order to obtain a cell density of 1 × 10 6 cells per ml.
27|
Plate the cells in six-well culture plates at a concentration of 1 × 10 6 cells per ml in a volume of 3-4 ml per well (or use a T-75 flask for larger cell numbers).  crItIcal step Cell density is critical to optimal activation of CD8 + T cells in our tests. Using a cell concentration <1 × 10 6 cells per ml results in lower RV transduction efficiency. ? trouBlesHootInG
28|
Incubate the cells at 37 °C and 5% CO 2 for 18-24 h. In the meantime, continue with the infection of the recipient mice (Step 29).
Infection of recipient mice • tIMInG 1-2 h 29| On the same day as when the CD8 + T cells are stimulated in vitro (Step 24), infect recipient mice with the desired pathogen (e.g., we use LCMV for P14 TCR Tg cells). We inject 2 × 10 5 plaque-forming units (p.f.u.) of Armstrong strain i.p. and 4 × 10 6 p.f.u. of clone 13 strain intravenously (i.v.) for acute and chronic infection, respectively. We use 28-gauge and 29-gauge insulin syringes for i.p. and i.v. injections, respectively. enrichment of activated cD8 + t cells by percoll • tIMInG 1 h 30| Leave 100% (vol/vol) isotonic Percoll and complete RPMI-1640 medium at room temperature for at least 1 h or use a water bath to bring the temperature up to 24 °C. Set the centrifuge at 25 °C.  crItIcal step The temperatures of the Percoll, medium, centrifuge and cell suspension are critical to optimal separation and recovery in density centrifugation. Make sure that all reagents and the centrifuge are prewarmed to room temperature before starting cell harvest. Always keep the cell suspension at room temperature during enrichment steps.
? trouBlesHootInG 31| Examine the T-cell morphology using an inverted light microscope.  crItIcal step At least 50% of the cells should be blasting, with an enlarged round shape and glossy appearance. In addition, there should be some cell aggregates, as activated T cells form ball-shaped aggregates in vitro.
32|
Harvest stimulated T cells from the six-well plate or a 75-cm 2 flask into a 50-ml conical tube. Before transferring to a tube, pass the cell suspension through a 70-µm sterile cell strainer to remove the cell aggregates.  crItIcal step Pipette the suspension up and down intensively until all non-adherent cells have been removed, as in vitro-stimulated day 1 effector cells are often firmly attached and form some cell aggregates. We usually do this 10-20 times with a 5-ml pipette with no negative effect on cell viability.  crItIcal step To maximize cell recovery, grind the cell aggregates on a 70-µm strainer using the plunger of a 5-ml syringe. 
70|
Transfer the cells to a 24-or 48-well cell culture plate, and incubate the plate overnight at 37 °C, 5% CO 2 (Fig. 1) .
71|
On day 2, harvest the CD8 + T cells from the tissue culture plate. Check the transduction efficiency by flow cytometry. Stain for surface markers (e.g., CD8, congenic markers and Thy1.1 or hNGFR for RV detection, if necessary).
analysis of rV-transduced cD8 + t cells in vivo • tIMInG 4-10 h 72| Bleed or harvest target organs from recipient mice after the desired time.  crItIcal step For a typical infection model, such as LCMV, the following three time points are preferred for an initial screening experiment: day 8 (up to day 10) to determine the magnitude of effector proliferation, day 15 (up to day 18) to examine contraction, and day 30 and onward to examine development, differentiation and stability of memory or exhausted T cells.
73|
Prepare a single-cell suspension using standard cellular immunology protocols, and stain cell-surface markers for flow cytometry.  crItIcal step We have noticed that at some time points (particularly days 6-8), there was substantial loss of RV-transduced CD8 + T cells during single-cell preparation when prepared with Histopaque density centrifugation. It is possible that RV-transduced CD8 + T cells have slightly altered cell density during the effector phase. Use of RBC lysis buffer at this point is recommended.
74|
If intracellular molecules are stained in the cells that were transduced with RV with fluorescent protein marker (e.g., GFP, VEX, mKO2), pre-fix the samples with 2% (wt/vol) PFA in PBS for 20 min at 4 °C before applying fixation buffer from commercial ICS kits. ! cautIon PFA is toxic. Wear appropriate personal protective equipment.  crItIcal step Additional fixation prevents loss of cytoplasmic fluorescent protein signal and improves the detection of RV-transduced T cells (Fig. 7) . ? trouBlesHootInG 75| Analyze the samples by flow cytometry.
? trouBlesHootInG Troubleshooting advice can be found in table 1. 
